New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. by Rose, Christiane et al.
New highly sensitive rodent and human tests for soluble
amyloid precursor protein alpha quantification:
preclinical and clinical applications in Alzheimer’s
disease.
Christiane Rose, Katell Peoc’H, Ste´phanie Chasseigneaux, Claire Paquet,
Julien Dumurgier, Fanchon Bourasset, Fre´de´ric Calon, Jean-Louis Laplanche,
Jacques Hugon, Bernadette Allinquant
To cite this version:
Christiane Rose, Katell Peoc’H, Ste´phanie Chasseigneaux, Claire Paquet, Julien Dumurgier, et
al.. New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha
quantification: preclinical and clinical applications in Alzheimer’s disease.. BMC Neuroscience,
BioMed Central, 2012, 13 (1), pp.84. <10.1186/1471-2202-13-84>. <inserm-00723764>
HAL Id: inserm-00723764
http://www.hal.inserm.fr/inserm-00723764
Submitted on 13 Aug 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

METHODOLOGY ARTICLE Open Access
New highly sensitive rodent and human tests
for soluble amyloid precursor protein alpha
quantification: preclinical and clinical applications
in Alzheimer’s disease
Christiane Rose1, Katell Peoc’h2, Stéphanie Chasseigneaux1,2, Claire Paquet3,4,5, Julien Dumurgier3,
Fanchon Bourasset2, Frédéric Calon6, Jean-Louis Laplanche2, Jacques Hugon3,4,5 and Bernadette Allinquant1*
Abstract
Background: Amyloid precursor protein (APP), a key molecule in Alzheimer’s disease (AD), is metabolized in two
alternative cleavages, generating either the amyloidogenic peptides involved in AD pathology or the soluble form
of APP (sAPPα). The level of amyloidogenic peptides in human cerebrospinal fluid (CSF) is considered to be a
biomarker of AD, whereas the level of sAPPα in CSF as a biomarker has not been clearly established. sAPPα has
neurotrophic and neuroprotective properties. Stimulating its formation and secretion is a promising therapeutic
target in AD research. To this end, very sensitive tests for preclinical and clinical research are required.
Methods: The tests are based on homogenous time-resolved fluorescence and require no washing steps.
Results: We describe two new rapid and sensitive tests for quantifying mouse and human sAPPα. These
20 μl-volume tests quantify the levels of: i) endogenous mouse sAPPα in the conditioned medium of mouse
neuron primary cultures, as well as in the CSF of wild-type mice, ii) human sAPPα in the CSF of AD mouse models,
and iii) human sAPPα in the CSF of AD and non-AD patients. These tests require only 5 μl of conditioned medium
from 5× 104 mouse primary neurons, 1 μl of CSF from wild-type and transgenic mice, and 0.5 μl of human CSF.
Conclusions: The high sensitivity of the mouse sAPPα test will allow high-throughput investigations of molecules
capable of increasing the secretion of endogenous sAPPα in primary neurons, as well as the in vivo validation of
molecules of interest through the quantification of sAPPα in the CSF of treated wild-type mice. Active molecules
could then be tested in the AD mouse models by quantifying human sAPPα in the CSF through the progression
of the disease. Finally, the human sAPPα test could strengthen the biological diagnosis of AD in large clinical
investigations. Taken together, these new tests have a wide field of applications in preclinical and clinical studies.
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Background
Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by cognitive deficits leading to a progres-
sive loss of functional autonomy. The neuropathological
hallmarks of the disease are extracellular amyloid depos-
its and intracellular neurofibrillar tangles containing
phosphorylated Tau (pTau) [1]. According to recently
proposed AD diagnostic criteria, diagnosis is based on
clinical criteria, medical history, neuropsychological
evaluation, morphological neuroimaging, cerebrospinal
(CSF) biomarkers and/or molecular imaging (PET scan)
[2]. AD is biologically characterized by the combination
of low Aβ1-42 peptide levels and high levels of total Tau
and Tau phosphorylated on threonine 181 (pTau181) in
the CSF [3-6]. However, new biomarkers are needed to
better discriminate AD from non-AD patients and to
improve the diagnosis of AD in patients with atypical
CSF profiles.
Amyloid precursor protein (APP) is a key molecule
in AD pathology. Proteolytic cleavages of APP by the
sequential actions of β- and γ-secretases form the neuro-
toxic amyloid beta (Aβ) peptide, which typically consists
of 40 or 42 amino acid residues (the amyloidogenic
pathway). An alternative cleavage by α-secretase, which
splits the APP sequence in the middle of the amyloid
peptide sequence, prevents formation of the Aβ peptide
and releases the resulting APP N-terminal ectodomain
(sAPPα)[7-9]. The physiological regulation of β and α
cleavages is poorly established. However, recent papers
describe an α cleavage following the β cleavage, as the
C-terminal fragment (C99) released after β-secretase
cleavage can be processed in α-secretase to generate the
C83 fragment [10]. In addition, truncated Aβ peptide of
14 to 16 residues generated from the sequential actions
of β and α-secretases have been identified in the CSF
[11]. Interestingly, an inhibitory domain for γ-secretase
activity in the C83 fragment has been identified able to
down regulate the production of Aβ peptide [12]. In
addition to its regulation of Aβ peptide, α-secretase
cleavage appears very important as sAPPα is involved in
several functions [13,14]. sAPPα is known for its neuro-
trophic and neuroprotective properties [13,14]. In
addition, it stimulates the proliferation of neuroblasts
from the sub-ventricular zone and increases long-term
potentiation [15,16].
Recent studies have investigated sAPPα as a putative
biomarker of AD [17,18] and tested the hypothesis that
dysregulation of the alternative cleavage of APP may
contribute to the pathophysiology of the disease. In the
past, human sAPPα has been evaluated by western blot-
ting [19-22], ELISA [23,24], and multiplex technology
[17,18,25]. However, some of the findings regarding
sAPPα levels in human CSF have been contradictory.
Such discordant results signal the need for an ideal
test that allows very sensitive and specific detection of
sAPPα in small amounts of human CSF. Recently, a new
technology (Alpha ScreenTM) [26] requiring no washing
and using low sample volume has been applied to sAPPα
(AlphaLISA) but no results have been published yet.
From a research perspective, sAPPα quantification in
preclinical studies in rodents is also necessary to better
understand AD pathophysiology and to develop new
therapeutic targets. Different cell lines, which include
neuroblastoma cells, are currently being used to study
APP metabolism in vitro. Although rodent primary
neurons produce low amounts of Aβ peptide [27], this
model remains interesting to study the response of
sAPPα to AD therapeutic drug candidates before their
in vivo validation in mice or rats. To effectively evaluate
these models, a sensitive, reproducible and rapid test is
needed to accurately assess sAPPα levels in the condi-
tioned medium of rodent neuron primary cultures and
to create high-throughput drug screening assays. Tests
are also needed for the in vivo evaluation of candidate
drugs identified in in vitro screens, both in wild-type
mice and in transgenic AD mouse models.
We describe two new rapid and sensitive sAPPα tests
that are based on homogenous time-resolved fluores-
cence (HTRF) and can be used to quantify the levels of:
i) endogenous rodent sAPPα in the conditioned medium
of mouse primary neurons, as well as in the CSF of wild
type mice; ii) human sAPPα in the CSF of AD mouse
models; and iii) human sAPPα in the CSF of AD and
non-AD patients. These tests require only 5 μl of condi-
tioned medium from 5× 104 mouse primary neurons,
1 μl of CSF from wild-type and transgenic AD mouse
models or 0.5 μl of human CSF.
Results and discussion
We developed two new sAPPα assays using an adapta-
tion of the HTRF technology: one detects mouse/
rodent-sAPPα (r-sAPPα) and the other human-sAPPα
(h-sAPPα) through the application of two different
APP antibodies (Figure 1). Both tests are single-step
homogenous assays that require no washing unlike most
ELISA procedures. This absence of multiple washing
steps increases the speed and reproducibility of the assay.
The final volume of the test is 20 μl, which allows detec-
tion in a 384-well plate for high-throughput investiga-
tions. These tests are extremely easy to use and require
few preanalytical preparations.
Analytical performance of the HTRF sAPPα assays
The purity of the standard recombinant proteins h-sAPPα
and r-sAPPα was checked by SDS-PAGE (Figure 2A).
We evaluated the specificity of the h-sAPPα assay using
human-sAPPβ (h-sAPPβ) and r-sAPPα recombinant pro-
teins, which both contain the MAB 348 epitope, and the
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human peptide Aβ1-42 (h-Aβ1-42), which contains the
6E10 epitope; both epitopes are necessary for h-sAPPα
assay. The signal obtained with 3− 200 ng/ml of h-sAPPβ,
r-sAPPα and h-Aβ1-42 was similar to that obtained for
the blank, demonstrating that the h-sAPPα does not
cross-react with any of these negative controls (Figure 2B).
We evaluated the specificity of the r-sAPPα assay using re-
combinant h-sAPPα, h-sAPPβ and the h-Aβ1-42 peptide.
We detected a cross-reactivity level of 23% with h-sAPPα,
indicating that the rodent C-terminal sAPPα antibody is
less specific than the human sAPPα 6E10 antibody (slope
for r-sAPPα: 0.73±0.02, slope for h-sAPPα: 0.17±0.01).
No cross-reactivity was observed with h-sAPPβ or h-Aβ1-
42 (Figure 2C).
We obtained a linear response using 3− 200 ng/ml of
recombinant h-sAPPα or r-sAPPα, which indicated that
the limit of detection was approximately 3 ng/ml
(Figure 2B, C). We then evaluated the linearity of both
assays with serial dilutions of human (h-) or mouse (r-)
CSF. In both cases, the slopes obtained with h-CSF
(1.39 ± 0.04) and r-CSF (0.90 ± 0.07) were parallel to the
standard curves generated by recombinant human
(1.49 ± 0.05) and rodent (0.88 ± 0.06) sAPPα, respectively.
These results demonstrate that sAPPα levels in the CSF
can be accurately evaluated in these assays with only
0.5 μl (5 μl diluted 1/10) of h-CSF or 1 μl (5 μl diluted
1/5) of r-CSF (Figure 3A, B).
To assess the intra- and inter-assay imprecision of the
h-sAPPα assay, five h-CSF samples were each tested ten
times on one plate in the same experiment and were
tested three times in three independent experiments.
The mean values for intra- and inter-assay imprecision
were <5% with one exception in each experiment.
Imprecision was 6.6% for one CSF sample in the intra-
assay experiment and 8.3% for a different CSF sample in
the inter-assay experiment (Table 1).
To assess the intra- and inter-assay imprecision of the
r-sAPPα assay, three samples of conditioned media from
mouse neuron primary cultures were each tested ten
times on one plate in the same experiment and were
each tested three times in three independent experi-
ments. The mean values for the intra- and inter-assay
imprecision were below 6% and 7%, respectively, with
one exception of 11.4% for one sample in the inter-assay
experiment (Table 2).
We then examined the stability of h-CSF sAPPα. First,
we evaluated the effect of storage in polypropylene or
polystyrene tubes. Five samples were divided into poly-
propylene or polystyrene tubes and stored for 24 hours
at −80°C. The h-sAPPα values of samples stored in poly-
styrene tubes were not significantly different from those
of samples stored in polypropylene tubes (mean recov-
ery: 93 ± 2%; Table 3), which is a real concern in a clin-
ical practice [28-30].
Next, we evaluated whether storage temperature
affected the stability of h-sAPPα. Five aliquots of h-CSF
were stored for 24 hours at −80°C, −20°C, +4°C or room
temperature, or were stored at −80°C and subjected to
three freeze/thaw cycles during three days. No signifi-
cant differences were detected for the different storage
conditions or for the samples that underwent the three
freeze/thaw cycles. Thus, sAPPα in CSF appears to be
very stable (Table 4).
sAPPα assay development: in vitro applications
We used our sAPPα assays to measure the sAPPα levels
in the conditioned media of human neuroblastoma cells
and mouse neuron primary cultures.
Human neuroblastoma cells and mouse primary neu-
rons were plated in 96-well plates. We first determined
whether sAPPα secretion was proportional to the num-
ber of cells per well and to the time of incubation
(Figure 4A, B). sAPPα secretion from cultured cells can
be enhanced in vitro by the PKC-mediated stimulation
of the metalloprotease ADAM17 [31-33]. The neuropep-
tide PACAP 27 [34] promotes the α-secretase-mediated
cleavage of full-length APP through the constitutive
ADAM10 metalloprotease. The green tea polyphenol
EGCG stimulates either ADAM10 or ADAM17,
depending on the cell type being treated [35,36]. We
APP protein
Aβ
Human (6E10) or rodent
C-terminal specific antibodies
sAPPα
sAPPβ
Membrane
MAB348
(22C11)
N C
Figure 1 Antibodies used for human and rodent sAPPα tests. For the human assay, the antibody 6E10 (specific for h-Aβ1-16) binds to a
h-sAPPα epitope, which differs from the r-sAPPα by three amino acids. In the rodent assay, this antibody is substituted by a rodent Aβ1-16-specific
antibody. Furthermore, this epitope is absent from sAPPβ, hence, these two C-terminal sAPPα antibodies determine the specificity of
the assay whereas MAB 348 (22C11) detects both human and rodent N-terminal fragments.
Rose et al. BMC Neuroscience 2012, 13:84 Page 3 of 11
http://www.biomedcentral.com/1471-2202/13/84
treated 3 x 104 neuroblastoma cells with PDBu (a PKC
activator) to evaluate its impact on the levels of sAPPα
produced in conditioned media. We demonstrated that
0.01 to 0.3 μM of PDBu treatment caused a dose-
dependent increase in the level of h-sAPPα in the condi-
tioned medium of neuroblastoma cells (Figure 4C). This
increase was completely abolished by treatment with the
PKC inhibitor GF-109203 or the α-secretase inhibitor
TAPI 0 (Figure 4D).
To further validate the new r-sAPPα assay, we used
mouse primary neurons, at six days in vitro. We first
checked by western blotting the presence of r-sAPPα in
the conditioned medium recognized by both 22C11 and
rodent specific C-terminal antibodies (Figure 5A). This
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Figure 3 Linearity of the CSF sAPPα assays. A: Human sAPPα
assay. Serial dilutions of h-CSF between 1/2.5 and 1/20 were
assayed and compared to serial dilutions of recombinant h-sAPPα at
concentrations between 0 ng/ml and 200 ng/ml. Results were
calculated from the 665 nm/620 nm ratios and expressed in delta
F. Slope for h-CSF: 1.35 ± 0.04; slope for recombinant h-sAPPα:
1.45 ± 0.05. B: Rodent sAPPα assay. Serial dilutions of r-CSF from 1/
2.5 to 1/10 were assayed and compared to serial dilutions of
recombinant r-sAPPα at concentrations between 0 ng/ml and
50 ng/ml. Results were calculated from the 665 nm/620 nm ratios
and expressed in delta F. Slope for r-CSF: 0.83 ± 0.04; slope for
recombinant r-sAPPα: 0.76 ± 0.04.
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Figure 2 Specificity of the assays. A: Recombinant proteins
h-sAPPα and r-sAPPα purity. 0.5 μg of h-sAPPα and r-sAPPα
separated in 10% SDS-PAGE and stained with Simply Blue Safe Stain.
The purity of both recombinant proteins is shown by the absence
of additional bands. B: Human sAPPα assay. Calibration curves were
generated with various concentrations of the recombinant proteins
h-sAPPα, h-sAPPβ, r-sAPPα and the commercially available human
peptide h-Aβ1-42. Results were calculated from the 665 nm/620 nm
ratios and expressed in delta F. Slope for h-sAPPα: 1.47 ± 0.05; slopes
for other peptides: <0.05. C: Rodent sAPPα assay. Calibration curves
were generated with various concentrations of the recombinant
proteins r-sAPPα, h-sAPPβ, h-sAPPα and the commercially available
peptide h-Aβ1-42. Results were calculated from the 665 nm/620 nm
ratios and expressed in delta F. Slope for r-sAPPα: 0.73 ± 0.02; slope
for h-sAPPα: 0.17 ± 0.01; slopes for other peptides: <0.05.
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sAPPα band at 100 kDa is specific of the isoform 695
present in neurons [37].
Mouse primary neurons were plated in 96 well-plates
at the density of 5 × 104 cells per well. We checked that
r-sAPPα secreted was proportional to the number of
neurons and to the time of incubation (Figure 5B,C).
Treatment of primary neurons with 30 μM EGCG or
with 1 μM PACAP-27 produced a strong increase in the
level of endogenous r-sAPPα in the incubation medium
(Figure 5D). These results from our rodent test validate
previously reported western blotting data from treated
neuroblastoma cells [34,35].
The rodent test detected sAPPα in only 5 μl of condi-
tioned medium from 5×104 primary neurons cultured in
96-well plates, without concentration of the proteins.
Five CSF samples were divided into polypropylene or
polystyrene tubes and stored for 24 hours at −80°C. Mean±
SEM of h-sAPPα in ng/ml and (%) compared to the aliquot
stored in polypropylene tubes. In previously published
reports, evaluating sAPPα in conditioned media required
higher numbers of cells combined with trichloracetic acid
precipitation of proteins [34], media lyophilization [35] or
protein concentration with centrifugal filters [36].
sAPPα assay development: in vivo applications in mice
To evaluate the feasibility of measuring sAPPα levels in
the CSF of mice, we used 14-month-old wild-type mice
and 12-month-old AD triple transgenic mice (3xTg AD)
[38]. The maximum volume of CSF obtained from one
mouse was 5 μl. sAPPα assays were performed on each
CSF sample diluted 1/5 or 1/10. The mean r-sAPPα con-
centrations in the CSF were 137 ± 17 ng/ml for wild-type
mice and 105 ± 8 ng/ml for 3xTg AD mice. In the 3×Tg
AD mice, the h-sAPPα concentration was 34 ± 6 ng/ml
(Table 5). In the 3×Tg AD mice, the h-sAPPα derived
from the transgene was specifically and distinctly quanti-
fied in the CSF relative to the endogenous r-sAPPα,
whereas the r-sAPPα may be contaminated by 23%
h-sAPPα (Figure 2C). One μl of mouse CSF was suffi-
cient to detect r-sAPPα as well as h-sAPPα and detection
was linear for serially diluted samples. This level of sensi-
tivity may allow the levels of the human transgenic
Table 2 Intra- and inter-assay imprecision in the r-sAPPα
assay
Intra-assay imprecision
Neuron conditioned medium r-sAPPα (ng/ml) CV (%)
1 23.4 ± 1.4 5.9
2 15.9 ± 0.7 4.4
3 17.4 ± 0.6 3.4
Inter-assay imprecision
Neuron conditioned medium r-sAPPα (ng/ml) CV (%)
1 24.7 ± 1.5 6.0
2 14.8 ± 1.7 11.4
3 18.6 ± 1.2 6.4
Intra-assay imprecision: three conditioned media samples from three different
experiments were tested ten times on one plate.
Inter-assay imprecision: the same samples were tested three times in three
independent assays. Mean ± SEM of r-sAPPα concentration (ng/ml). CV:
coefficient of variation (%).
Table 3 Stability of h-sAPPα in CSF stored at different
conditions
Effect of storing CSF in polypropylene and polystyrene tubes
Samples Polypropylene Polystyrene %
h-sAPPα (ng/ml) h-sAPPα (ng/ml)
1 669 ± 20 659 ± 41 98 ± 6
2 399 ± 20 391 ± 24 98 ± 6
3 456 ± 2.5 412 ± 16 90 ± 3
4 535 ± 16 482 ± 18 90 ± 3
5 236 ± 2 212 ± 7 89± 3
Five CSF samples were divided into polypropylene or polystyrene tubes and
stored for 24 hours at −80°C. Mean ± SEM of h-sAPPα in ng/ml and (%)
compared to the aliquot stored in polypropylene tubes.
Table 4 Stability of h-sAPPα in CSF stored at different
conditions
Effect of storage temperature
Samples −80°C −20°C +4°C RT F/T
1 100± 6 101 ± 5 100 ± 11 93 ± 1 103 ± 2
2 100± 7 93± 9 95± 15 85 ± 14 93 ± 6
3 100± 1 77± 1 82± 4 80± 4 76 ± 4
4 100± 5 113 ± 2 80± 4 109 ± 3 99 ± 5
5 100± 3 86± 5 81± 4 70± 5 83 ± 1
Five CSF samples were divided in five aliquots and stored for 24 hours at one
of several different temperatures including room temperature (RT), or stored at
−80°C and exposed to three freeze/thaw cycles (F/T) within a period of three
days.
The results were normalized (%) for the results from the aliquot stored at −80°C.
Table 1 Intra- and inter-assay imprecision in the h-sAPPα
Intra-assay imprecision
Human CSF sample h-sAPPα (ng/ml) CV (%)
1 705 ± 13 1.8
2 432 ± 18 4.1
3 434 ± 16 3.6
4 556 ± 21 3.7
5 270 ± 18 6.6
Inter-assay imprecision
Human CSF sample h-sAPPα (ng/ml) CV (%)
1 703 ± 24 3.4
2 424 ± 21 4.9
3 503 ± 17 3.3
4 493 ± 41 8.3
5 338 ± 17 5.0
Intra-assay imprecision: five CSF samples were tested ten times on one plate.
Inter-assay imprecision: the same samples were tested three times in three
independent experiments. Mean ± SEM of h-sAPPα concentration (ng/ml).
CV: coefficient of variation (%).
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sAPPα to be followed through the progression of the dis-
ease, which has never been reported previously.
sAPPα assay development: in vivo applications in human
We then assessed h-sAPPα levels in the CSF of AD and
non-AD patients. High levels of h-sAPPα in the CSF
determined using a multiplex technology were reported
to be associated with AD [17,18,25]. In this study, we
evaluated our h-sAPPα assay using CSF samples from
patients who had been classified according to validated
criteria as either non-AD or AD by a team specialized in
the diagnosis of neurodegenerative disorders (CP, JD,
JH). These patients were matched according to sex and
age and significantly differ by the MMSE test (Table 6).
We checked by western blotting in some CSF samples
the presence of two sAPPα isoforms recognized by both
22C11 and 6E10 antibodies and the absence of specific
detectable cleaved isoforms (Figure 6A). The two sAPPα
isoforms of molecular weights (MW) 100 and 125 kDa
detected are similar to that observed in soluble fraction
of mouse brains (data not shown) and correspond to
mature glycosylated forms of sAPPα 695 [27,39]. How-
ever we cannot exclude that the higher isoform corres-
pond to the sAPPα 751 containing KPI domain and
present in glial cells [37,39]. The bands of lower MW
and lower intensity detected were non specific as recog-
nized by the anti-mouse secondary antibody (Figure 6A).
In our population, Aβ1-42 concentrations were lower
(−51%; p< 0.001; Figure 6C) and Tau and pTau181 con-
centrations were higher (+200% and +123%, respectively;
p< 0.001; Figure 6D, E) in the AD group than in the
non-AD group. We found significantly higher sAPPα
concentrations in AD CSF compared to non-AD CSF
(+30%; p< 0.01; Figure 6B), which agrees with recent
studies in which the sAPPα concentrations in CSF were
determined by a multiplex technology [17,18,25].
Furthermore, our test detected h-sAPPα in as little as
0.5 μl of CSF, which is a vast improvement over ELISA
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Figure 4 In vitro secretion of h-sAPPα by SH-SY5Y human neuroblastoma cells and its modulation by pharmacologic agents. A: Various
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tests and multiplex technology, which require sample
volumes of 100 μl and 25 μl, respectively. The low
amounts of CSF required by our test will allow large
clinical and longitudinal investigations in patients to val-
idate sAPPα as an AD biomarker.
Conclusions
This is the first description of two highly sensitive tests
that can be used to detect sAPPα in a variety of samples.
Samples include the conditioned media of human
neuroblastoma cells and mouse primary neurons, as well
as very small samples of biological fluids, such as mouse
and human CSF.
These new tools will have very wide applications from
pre-clinical to clinical studies. Together, their rapidity,
sensitivity and small incubation volumes will facilitate
high-throughput investigations of drugs capable of
increasing the secretion of endogenous sAPPα from
primary neurons. The tests may be subsequently vali-
dated for in vivo analyses by using them to evaluate at
different time points sAPPα levels in the CSF of wild-
type mice or AD mouse models treated with molecules
that exhibit activity in in vitro screening assays. Finally,
the human sAPPα test will allow sAPPα levels to be
measured in the CSF of patients participating in large
clinical investigations.
Methods
sAPPα assays
The quantification of human and rodent sAPPα was
achieved by adapting the HTRF technology developed by
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recognized both by 22C11 (2) and by the rodent C-terminal sAPPα antibodies (1). B: Various numbers of cortical neurons (between 104 and
7 × 104) were plated in 96-well plates in 0.1 ml final volume. After six days in culture, 60% of the conditioned medium was discarded and
replaced by fresh medium. 24 hours later, medium was collected and 5 μl of each sample was tested in duplicate in the r-sAPPα assay. C: 5 × 104
neurons were plated in 96-well plates in 0.1 ml final volume. After six days in vitro, 60% of the conditioned medium was discarded and replaced
by fresh medium. Medium was collected after incubations of 3 hours, 6 hours, 9 hours or 24 hours and 5 μl of each sample was tested in
duplicate in the r-sAPPα assay. D: 5 × 104 neurons were plated in 96-well plates in 0.1 ml final volume. After six days in vitro, 60% of the
conditioned medium was discarded and replaced by fresh medium. EGCG (30 μM) and PACAP-27 (1 μM) were added and the medium was
collected 24 hours later. 5 μl of each sample was tested in duplicate in the r-sAPPα assay. ***: p< 0.001.
Table 5 Measurement of sAPPα in mouse CSF
Mice r-sAPPα (ng/ml) h-sAPPα (ng/ml)
Wild-type (5) 137 ± 17 0
3xTg AD (7) 105 ± 8# 34 ± 6
CSF samples (2–5 μl) were collected from wild type or 3xTg AD mice and 1/5
or 1/10 dilutions of the CSF were tested in the r-sAPPα and in the h- sAPPα
assays.#: This value includes 23% of h- sAPPα (see Figure 2C).
Table 6 Patient characteristics
Group (n) Age± SEM M+F MMSE± SEM
Non AD (28) 68.9 ± 2.0 14 + 14 23.5 ± 0.7
AD (32) 72.4 ± 1.6 12 + 19 19.3 ± 1.0 **
AD: patients with Alzheimer’s disease; non-AD: patients with other dementias;
M: male; F: female. MMSE: mini mental state examination. **: p< 0.01.
Rose et al. BMC Neuroscience 2012, 13:84 Page 7 of 11
http://www.biomedcentral.com/1471-2202/13/84
Cisbio international company (Bagnol ssur Cèze, France).
It is a single step immunoassay that employs two pri-
mary antibodies. The first antibody for both tests is
directed to an epitope in the N-terminal domain of the
APP protein, which is common to humans and rodents
(22C11; MAB 348 from Chemicon, Billerica, MA, USA),
and coupled to Europium cryptate, a donor fluoro-
phore. The second antibody in each assay is specific
for the C-terminal domain of either h-sAPPα (6E10) or
r-sAPPα (SIG-39153; both antibodies are from Signet
laboratories, and purchased from Covance, Dedham,
MA, USA). Both of the secondaries antibodies were
coupled to an acceptor fluorophore, such as D2 (Figure 1).
When the donor and acceptor fluorophores are brought
together by a biomolecular interaction, i.e., when sAPPα
is present in the sample, a portion of the energy captured
by the donor fluorophore during excitation is released
through a fluorescence emission at 620 nm, while the
remaining energy is transferred to the acceptor. This
energy is then released by the acceptor as a specific fluor-
escence at 665 nm and is proportional to the concentra-
tion of sAPPα in the sample.
Recombinant h-sAPPα, r-sAPPα and h-sAPPβ were
produced in bacteria using a p-Gex vector and were
purified from bacterial lysates using the glutathione-S-
transferase system (GE Healthcare, Uppsala, Sweden), as
previously described [40]. Their purity was checked by
10% SDS-PAGE (Bio-Rad, Hercules, CA, USA). The
Aβ1-42 peptide was purchased from Bachem (Weil am
Rhein, Germany). Fluorophore labeling of antibodies was
done by Cisbio.
The assay was performed in a final volume of 20 μl
in a 384-well white plate (Proxiplate; Perkin Elmer,
Waltham, MA, USA). 5 μl of conditioned medium from
SH-SY5Y neuroblastoma cell cultures or from mouse
neurons in primary culture, 5 μl of rodent CSF dilutions
(1/2.5, 1/5, 1/10), 5 μl of human CSF dilutions (1/2.5,
1/5, 1/10, 1/20), or a calibration curve (human or rodent
recombinants APPα, at concentrations of 3–200 ng/ml)
in a 50 mM phosphate buffer pH 7.0 containing 0.2%
BSA and 10 mM DTT, were added to 5 ng of the cryp-
tate conjugate antibody and 20 ng of the D2 conjugate
antibody. Both antibodies were diluted in 50 mM phos-
phate buffer pH 7.0 containing 0.4 M potassium fluor-
ure. All measurements were performed in duplicate. For
the negative control, phosphate buffer replaced the cali-
bration curve. The plate covered with a plate sealer was
centrifuged for 1 min at 1000 x g and incubated over-
night at room temperature. Then, the plate sealer was
removed, and the plate was read on a compatible HTRF
reader (Envision; Perkin Elmer, Waltham, MA, USA) at
620 and 665 nm. Results were calculated from the
665 nm/620 nm ratio and expressed in delta F: Delta
F = ([test sample or calibration sample 665 nm/620 nm
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Figure 6 Concentrations of different biomarkers in the CSF of two groups of patients previously diagnosed as AD and non-AD. A: 4 μg
of CSF proteins were separated in 10% SDS-PAGE for western blotting. h-sAPPα (two isoforms) present in CSF are recognized by both the 6E10
(1) and the 22C11 (2) antibodies. The anti-mouse secondary antibody (3) recognized non specifically some bands. B-E: Concentrations of
biomarkers in the CSF of AD patients group were compared to those in the CSF of non-AD patients. **: p< 0.01; ***: p< 0.001.
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ratio −negative control 665 nm/620 nm ratio]/[negative
control 665 nm/620 nm ratio])×100. Delta F is propor-
tional to the sAPPα concentration.
Cell cultures
SH-SY5Y human neuroblastoma cells were obtained
from the ATCC and maintained at 37°C under 5% car-
bon dioxide/95% humidified air incubator in a DMEM
medium, supplemented with Glutamax, 10% fetal calf
serum (FCS), 0.1% penicillin/streptomycin. Cells were
plated (3 × 104 cells per well) in 96-well plates coated
with 10 μg/ml collagen. The next day, when cells were
60–80% confluent, the conditioned medium was dis-
carded and replaced by the same medium containing
1%N2 (Gibco, Paisley, UK) in place of FCS. Then,
10 μM GF-109203 (Sigma, St. Louis, MO, USA) and
30 μM TAPI 0 (Calbiochem, San Diego, CA, USA) were
added 1 hour before adding 0.3 μM PDBu (Sigma,
St. Louis, MO, USA) and the cells were incubated for
24 hours. After this period, conditioned media were col-
lected, centrifuged at 800 ×g for 5 min at room
temperature to remove any dead cells and the super-
natant was immediately supplemented with 1X complete
protease inhibitor cocktail (Roche, Bâle, Switzerland)
and 5 μl duplicate aliquots were tested in the h-sAPPα
assay or were stored at −20°C until the h-sAPPα assay.
Cortical neuron primary cultures were obtained from
E16 Swiss mouse embryos. Neurons were grown in a
defined medium free of serum and supplemented with
hormones, proteins, and salts as previously described
[41]. Briefly, dissociated cells were plated (5 × 104 neu-
rons per well) in 96-well plates coated with 1.5 μg/ml
polyornithin. After six days in vitro, 60% of the condi-
tioned medium was discarded and replaced by fresh
medium. Then, 30 μM EGCG or 1 μM PACAP-27
(Sigma, St. Louis, MO, USA) were added for a 24 hours
incubation. At the end of this period, conditioned media
were collected, centrifuged at 800 × g for 5 min at room
temperature and the supernatant was immediately sup-
plemented with 1X complete protease inhibitor cocktail
and 5 μl duplicate aliquots were tested in the r-sAPPα
assay or were stored at −20°C until the r-sAPPα assay.
Patients
60 patients were recruited from the Clinical and
Research Memory Center (CMRR) in Paris Lariboisière
Hospital, which is specialized in the care management of
patients with cognitive disorders. We included in this
study AD and non-AD patients for whom a lumbar
puncture (LP) had been performed between November
1st, 2008 and November 1st, 2011 to investigate potential
cognitive disorders. All patients had an extensive exam-
ination including clinical and neuropsychological evalua-
tions, biological measurements and brain imaging. Based
on all available information, patients were classified into
two groups (32 AD and 28 non-AD). Complex or un-
clear cases were discussed, and diagnoses were then set
by a multidisciplinary team of neurologists, geriatricians
and neuropsychologists. AD patients fit the criteria for
probable AD, as defined by the NINCDS-ADRDA [42],
and had biochemical CSF results associated with AD
(low Aβ1-42 levels, and high total Tau and pTau181
levels) [3-6].
Non-AD patients were diagnosed with other cognitive
disorders, according to validated criteria, including: vas-
cular dementia (n = 7), frontotemporal degeneration
(n = 3), depression (n = 2), anxiety (n = 4), Lewy body dis-
ease (n = 2), intoxication (n = 1), supranuclear palsy
(n = 1), chronic hydrocephalus (n = 2), alcoholism (n = 5),
and sleep apnea syndrome (n = 1). Patients with
unknown clinical diagnoses or who were not able to
undergo testing or a magnetic resonance imaging were
excluded. There was no Mild Cognitive Impairment
patients in our study. LPs were performed on fasting
patients in the month following their clinical diagnosis.
CSF was collected in 12 ml polypropylene tubes
(TC10PCS; CML, Nemours, France) in standardized
conditions and transferred within 4 hours to the labora-
tory. It was then rapidly centrifuged at 1800 × g for
10 min at 4°C. A small amount of CSF was used for rou-
tine analysis, including total cell count, bacteriologic
exam, total protein and glucose concentration. CSF was
aliquoted in polypropylene tubes of 1 ml and stored at
−80°C until use for further analysis.
Measurements of Aβ1-42, Tau and pTau181 levels in
CSF were performed by sandwich ELISA according
to the manufacturer’s protocols (Innogenetics, Ghent,
Belgium). A neurobiological AD profile was established
for all the patients in this study.
SDS-PAGE and western blotting analysis
Human and rodent sAPPα recombinant proteins
(0.5 μg), were separated in 10% SDS-PAGE (Criterion;
Bio-Rad, Hercules, CA, USA), and stained with Simply-
BlueSafeStain (Invitrogen Life Technologies, Paisley, UK).
For western blotting analysis, 0.6 ml of conditioned
medium at six days in vitro from 4× 105 cortical neurons
primary cultures were centrifuged at 800 x g for 5 min
at room temperature. The supernatant was precipitated
overnight at −20°C with five volumes of a cold mixture
10% trichloracetic acid/90% acetone. After centrifugation
at 15,000 × g for 20 min at 4°C, the pellet was washed
with cold acetone and dried. Then, the pellet was
resuspended in Laemmli buffer and an equal volume
was loaded in two wells in 10% SDS-PAGE. After migra-
tion, the proteins were transferred onto polyvinylidene
fluoride (PVDF) membranes (Immobilon; Millipore,
Billerica, MA, USA) and blocked in 5% low fat milk in
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Tris buffer saline, 0.02% Tween 20 (TBST). Membranes
were incubated overnight with the appropriate primary
antibody, 22C11 (1 μg/ml) or the rodent specific SIG-
39153 (2 μg/ml) in TBST. Then after 5 washings in
TBST, species-specific peroxidase-conjugated secondary
antibodies were incubated 45 min at room temperature.
After 5 washings the peroxidase signal was visualized
using ECL (Western Blotting Detection Reagents; GE
Healthcare, Uppsala, Sweden).
Human cerebrospinal fluid (4 μg protein) was diluted
in Laemmli buffer and loaded in 10% SDS-PAGE. After
migration, and transfer onto PVDF membranes, the
membranes were processed as above with the appropri-
ate primary antibody, 22C11 (1 μg/ml) or human spe-
cific 6E10 (2 μg/ml).
Ethics statement
All animal procedures followed the French and European
Union regulations. The protocols of animal anesthesia
and biological fluid punctures were performed according
to French government ethical laws decree 86/109 and
approved by the local Ethics Committee (Direction
départementale des services vétérinaires de Paris, service
de la protection et santé animales et de la protection de
l’environnement), permit number: 75–354.
For the clinical study, the research project was
approved by the Ethics Committee of Paris University
Hospitals (CEERB Bichat University Hospital, Paris,
France). All patients or caregivers gave their written
informed consent for CSF assessment.
Mouse CSF sampling
We used seven triple transgenic mice (3xTg AD, 12-
months-old) harboring three mutant genes: β-amyloid
precursor protein (APPswe), presenilin-1 (M146V)
knock-in, and Tau (P301L) [38] and five non-transgenic
controls (14-months-old). CSF from anesthetized mice
was taken from the cisterna magna using a glass capil-
lary, according to the method of Fisher et al. [43]. The
procedure was performed to keep blood contamination
to a minimum. Samples of 2 to 5 μl were transferred dir-
ectly to a microvial, centrifuged, and the supernatant
immediately frozen on dry ice, and then stored at −20°C
until rodent and human sAPPα assays were performed.
Statistical analysis
Statistical differences between groups were analyzed
using the unpaired Student’s t-test. Differences were con-
sidered significant if p< 0.05 (GraphPad Prism software,
La Jolla, CA, USA).
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